HepatologyNews.net

Hepatology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Farmaexplorer.it

Results from a phase III study presented at the International Liver Congress 2014 have shown Obeticholic acid ( OCA ) given to patients suffering from primary biliary cirrhosis ( PBC ) who previously ...


The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected ...


Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented at the International Liver Congress 2014 showed that Simeprevir ( Olysio )150 mg once-daily for 12 weeks in comb ...


In a study involving treatment-naive and treatment-experienced patients of Egyptian ancestry with chronic genotype 4 HCV infection, Sofosbuvir ( Sovaldi ) plus Ribavirin was shown to provide a simple, ...


Epidemiological, genetic and clinical data presented at the International Liver Congress 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment ...


Low-dose oral Interferon could exert immune-modulating effects in human. Researchers have conducted a clinical trial to investigate the efficacy of oral Interferon-alpha in preventing hepatitis C rela ...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin has showed efficacy against the hepatitis C ...


A phase III study has enrolled 217 patients with primary biliary cirrhosis who had either failed to get an adequate response with UDCA ( Ursodeoxycholic acid ), or had been unable to tolerate it. Pa ...


Researchers have determined that sarcopenia, a loss of skeletal muscle mass, increases risk of sepsis and mortality risk in patients undergoing live donor liver transplantation. Findings published in ...


All-oral combination therapy is desirable for patients with chronic hepatitis C virus ( HCV ) infection. Researchers evaluated Daclatasvir ( an HCV NS5A replication complex inhibitor ) plus Sofosbuvir ...


The existence of a direct pathogenic link between hepatitis C virus ( HCV ) infection and myocardial injury has not been confirmed. Researchers have investigated the association between myocardial con ...


Whether long-term suppression of replication of hepatitis B virus ( HBV ) has any beneficial effect on regression of advanced liver fibrosis associated with chronic HBV infection remains unclear. A s ...


Rifaximin ( Normix, Xifaxan ) is a gut-selective, oral antimicrobial agent shown to reduce the recurrence of overt hepatic encephalopathy ( HE) and HE-related hospitalizations in a 6-month, randomized ...


The stability and propagation of hepatitis C virus ( HCV ) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 ( miR-122 ). Miravirsen is a locked nucleic ...


Patients chronically infected with hepatitis C virus ( HCV ) genotype 2 or 3 for whom treatment with Peginterferon is not an option, or who have not had a response to prior interferon treatment, curre ...